Lord, Abbett & Co. LLC Arcellx, Inc. Transaction History
Lord, Abbett & Co. LLC
- $31.4 Billion
- Q3 2024
A detailed history of Lord, Abbett & Co. LLC transactions in Arcellx, Inc. stock. As of the latest transaction made, Lord, Abbett & Co. LLC holds 891,848 shares of ACLX stock, worth $56.2 Million. This represents 0.24% of its overall portfolio holdings.
Number of Shares
891,848
Previous 891,848
-0.0%
Holding current value
$56.2 Million
Previous $74.5 Million
-0.0%
% of portfolio
0.24%
Previous 0.24%
Shares
17 transactions
Others Institutions Holding ACLX
# of Institutions
205Shares Held
44.1MCall Options Held
2.23MPut Options Held
907K-
Paradigm Biocapital Advisors LP New York, NY4MShares$252 Million12.04% of portfolio
-
Perceptive Advisors LLC New York, NY3.89MShares$245 Million8.48% of portfolio
-
Nea Management Company, LLC Timonium, MD3.75MShares$236 Million23.89% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$222 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.46MShares$155 Million0.0% of portfolio
About Arcellx, Inc.
- Ticker ACLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,819,200
- Market Cap $2.76B
- Description
- Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...